Date published: 2025-11-7

00800 4573 8000

SCBT Portrait Logo
Seach Input

HRG-β3 Inhibidores

HRG-β3 inhibitors are a class of compounds designed to specifically target and inhibit the activity of HRG-β3, a member of the heregulin family of proteins. HRG-β3 (heregulin-β3) is one of several isoforms of the heregulin protein family that plays a crucial role in various cellular signaling pathways. These inhibitors work by binding to HRG-β3 and preventing its interaction with receptors such as ErbB3 and ErbB4, which are part of the ErbB receptor family. By interfering with HRG-β3's ability to engage with its target receptors, the inhibitors modulate the downstream signaling cascades that are typically triggered by HRG-β3's activity, affecting cellular processes such as growth, differentiation, and intracellular communication.

HRG-β3 inhibitors can vary widely depending on their chemical makeup, but they generally possess moieties that enable selective binding to HRG-β3. These compounds are often designed with high specificity for HRG-β3 to minimize off-target effects on other proteins. The design of HRG-β3 inhibitors is guided by structural biology, which allows for precise interactions at the molecular level, ensuring that the binding affinity is strong enough to effectively block HRG-β3 function. HRG-β3 inhibitors may be synthesized using organic chemistry techniques or discovered through high-throughput screening of chemical libraries. Their development involves fine-tuning molecular features such as hydrophobicity, charge distribution, and molecular size to optimize their performance in biochemical environments.

Nombre del productoNÚMERO DE CAS #Número de catálogoCantidadPrecioMENCIONESClasificación

Telmisartan

144701-48-4sc-204907
sc-204907A
50 mg
100 mg
¥801.00
¥1038.00
8
(1)

Antagonista de los receptores de la angiotensina II, podría influir en la función vascular y en las vías de señalización relacionadas.

Losartan

114798-26-4sc-353662
100 mg
¥1433.00
18
(1)

Otro antagonista de los receptores de la angiotensina II, que puede afectar a la presión arterial y a la angiogénesis.

Atorvastatin

134523-00-5sc-337542A
sc-337542
50 mg
100 mg
¥2843.00
¥5585.00
9
(1)

Inhibe la HMG-CoA reductasa, influyendo potencialmente en los niveles de colesterol y en la señalización celular relacionada con la inflamación y la angiogénesis.

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
¥2031.00
¥3554.00
2
(0)

Inhibe múltiples tirosina quinasas implicadas en la angiogénesis, afectando potencialmente a procesos en los que la HRG-β3 podría estar implicada.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
¥1230.00
¥3949.00
8
(0)

Modula las respuestas inmunitarias e inhibe la angiogénesis, lo que podría influir en las vías relacionadas con HRG-β3.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
¥632.00
¥2933.00
¥4693.00
129
(3)

Inhibe las quinasas RAF y otros receptores, podría afectar a la proliferación celular y la angiogénesis.

Metformin

657-24-9sc-507370
10 mg
¥869.00
2
(0)

Activa la AMPK, influyendo potencialmente en las vías metabólicas y el crecimiento celular relacionados con la HRG-β3.

Ibrutinib

936563-96-1sc-483194
10 mg
¥1726.00
5
(0)

Inhibe la tirosina quinasa de Bruton, podría afectar a la señalización de las células B y a las respuestas inmunitarias.